GLOSSARY

Clinical study: Clinical studies are research studies that evaluate potential medicines by testing them in a group of people. They are the primary way researchers determine the safety and efficacy of potential treatment.

Efficacy: The ability of a medication to produce a desired, beneficial outcome. In a clinical study, the efficacy of a drug is evaluated in patients.

FDA: This is the abbreviation for the Food and Drug Administration, which is the federal agency of the United States responsible for supervising the development and approval of prescription medications.

Geneticist: A scientist who has special training in the study of genes and heredity (the passing of genetic information from parents to their children). A medical geneticist is a doctor who specializes in diagnosing and treating genetic disorders or conditions.

MRI: A magnetic resonance imaging (MRI) scan produces an image of the body using strong magnet and radio waves. An MRI can help your child’s doctor identify plexiform neurofibromas and can also help them see if your child is responding to treatment.

Neurologist: A neurologist is a medical doctor who specializes in treating diseases of the nervous system: the brain, and the spinal column and nerves. Neurologists may treat NF1 PN (which is a noncancerous tumor of the nerves).

NF1 (neurofibromatosis type 1): NF1 is a rare progressive condition caused by a mutation or flaw in a particular gene. NF1 is usually diagnosed in childhood. It appears in an estimated 1 out of every 3000 infants.

Oncologist: An oncologist is a medical doctor who specializes in treating cancerous and noncancerous tumors. They are usually part of the healthcare team that treats patients with NF1 PN.

PN (plexiform neurofibromas): Benign (noncancerous) tumors that grow along a nerve. Plexiform neurofibromas can develop anywhere in the body, and their size can vary from small to large.

Side effects: Also called adverse events, they are unwanted reactions that happen as a result of taking a medication.

Tumor reduction: Describes what happens when the size of a tumor gets smaller.

Read More

IMPORTANT SAFETY INFORMATION

Before taking Koselugo, tell your healthcare provider about all of your medical conditions, including if you:

  • have heart problems
  • have eye problems
  • are pregnant or plan to become pregnant. Koselugo can harm your unborn baby
    • Females who could become pregnant and males with female partners who could become pregnant should use effective birth control (contraception) during treatment with Koselugo and for 1 week after your last dose
    • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Koselugo
  • are breastfeeding or plan to breastfeed. It is not known if Koselugo passes into your breast milk
    • Do not breastfeed during treatment with Koselugo and for 1 week after your last dose
    • Talk to your healthcare provider about the best way to feed your baby during this time

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Especially tell your healthcare provider if you are taking aspirin, blood thinners, or other medicines to treat blood clots. Koselugo contains vitamin E, which may increase your risk of bleeding.

Koselugo may cause serious side effects, including:

Heart problems. Koselugo can lower the amount of blood pumped by your heart, which is common and can also be severe. Your healthcare provider will do tests before and during treatment with Koselugo to check how well your heart is working. Tell your healthcare provider right away if you get any of the following signs or symptoms:

  • persistent coughing or wheezing
  • shortness of breath
  • swelling of your ankles and feet
  • tiredness
  • increased heart rate

Eye problems. Koselugo can cause eye problems that can lead to blindness. Your healthcare provider will check your vision before and during treatment with Koselugo. Tell your healthcare provider right away if you get any of the following signs or symptoms:

  • blurred vision
  • loss of vision
  • dark spots in your vision (floaters)
  • other changes to your vision

Severe diarrhea. Diarrhea is common with Koselugo and can also be severe. Tell your healthcare provider right away the first time that you get diarrhea during treatment with Koselugo. Your healthcare provider may give you medicine to help control your diarrhea and may tell you to drink more fluids.

Skin rash. Skin rashes are common with Koselugo and can also be severe. Tell your healthcare provider if you get any of the following signs or symptoms:

  • rash that covers a large area of your body
  • peeling skin
  • blisters

Muscle problems (rhabdomyolysis). Muscle problems are common with Koselugo and can also be severe. Treatment with Koselugo may increase the level of a muscle enzyme in your blood, which may be a sign of muscle damage. Your healthcare provider should do a blood test to check your muscle enzyme levels before you start taking Koselugo and during treatment. Tell your healthcare provider right away if you get any of the following signs or symptoms:

  • muscle aches or pain
  • muscle spasms and weakness
  • dark, reddish urine

Your healthcare provider may change your dose, temporarily stop, or permanently ask you to stop taking Koselugo if you have any of these side effects.

The most common side effects of Koselugo are:

  • vomiting
  • stomach pain
  • nausea
  • dry skin
  • feeling of tiredness, weakness, or lacking energy
  • muscle and bone pain
  • fever
  • inflammation of the mouth
  • headache
  • redness around the fingernails
  • itching

These are not all the possible side effects of Koselugo.

INDICATION

What is Koselugo?

Koselugo is a prescription medicine that is used to treat children 2 years of age and older with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas that cannot be completely removed by surgery.

It is not known if Koselugo is safe and effective in children under 2 years of age.

You may report side effects related to AstraZeneca products by clicking here.

IMPORTANT SAFETY INFORMATION

Before taking Koselugo, tell your healthcare provider about all of your medical conditions, including if you:

  • have heart problems
  • have eye problems
  • are pregnant or plan to become pregnant. Koselugo can harm your unborn baby
    • Females who could become pregnant and males with female partners who could become pregnant should use effective birth control (contraception) during treatment with Koselugo and for 1 week after your last dose
    • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Koselugo
  • are breastfeeding or plan to breastfeed. It is not known if Koselugo passes into your breast milk
    • Do not breastfeed during treatment with Koselugo and for 1 week after your last dose
    • Talk to your healthcare provider about the best way to feed your baby during this time

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Especially tell your healthcare provider if you are taking aspirin, blood thinners, or other medicines to treat blood clots. Koselugo contains vitamin E, which may increase your risk of bleeding.

Koselugo may cause serious side effects, including:

Heart problems. Koselugo can lower the amount of blood pumped by your heart, which is common and can also be severe. Your healthcare provider will do tests before and during treatment with Koselugo to check how well your heart is working. Tell your healthcare provider right away if you get any of the following signs or symptoms:

  • persistent coughing or wheezing
  • shortness of breath
  • swelling of your ankles and feet
  • tiredness
  • increased heart rate

Eye problems. Koselugo can cause eye problems that can lead to blindness. Your healthcare provider will check your vision before and during treatment with Koselugo. Tell your healthcare provider right away if you get any of the following signs or symptoms:

  • blurred vision
  • loss of vision
  • dark spots in your vision (floaters)
  • other changes to your vision

Severe diarrhea. Diarrhea is common with Koselugo and can also be severe. Tell your healthcare provider right away the first time that you get diarrhea during treatment with Koselugo. Your healthcare provider may give you medicine to help control your diarrhea and may tell you to drink more fluids.

Skin rash. Skin rashes are common with Koselugo and can also be severe. Tell your healthcare provider if you get any of the following signs or symptoms:

  • rash that covers a large area of your body
  • peeling skin
  • blisters

Muscle problems (rhabdomyolysis). Muscle problems are common with Koselugo and can also be severe. Treatment with Koselugo may increase the level of a muscle enzyme in your blood, which may be a sign of muscle damage. Your healthcare provider should do a blood test to check your muscle enzyme levels before you start taking Koselugo and during treatment. Tell your healthcare provider right away if you get any of the following signs or symptoms:

  • muscle aches or pain
  • muscle spasms and weakness
  • dark, reddish urine

Your healthcare provider may change your dose, temporarily stop, or permanently ask you to stop taking Koselugo if you have any of these side effects.

The most common side effects of Koselugo are:

  • vomiting
  • stomach pain
  • nausea
  • dry skin
  • feeling of tiredness, weakness, or lacking energy
  • muscle and bone pain
  • fever
  • inflammation of the mouth
  • headache
  • redness around the fingernails
  • itching

These are not all the possible side effects of Koselugo.

INDICATION

What is Koselugo?

Koselugo is a prescription medicine that is used to treat children 2 years of age and older with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas that cannot be completely removed by surgery.

It is not known if Koselugo is safe and effective in children under 2 years of age.

You may report side effects related to AstraZeneca products by clicking here.

Read More
Back to top